NCT07149857 - A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2025

Primary Completion Date

January 3, 2028

Study Completion Date

December 29, 2028

Conditions

Multiple Myeloma

Interventions

DRUG

Cilta-cel

Cilta-cel will be administered as intravenous infusion.

DRUG

Cyclophosphamide

Cyclophosphamide will be administered as intravenous infusion.

DRUG

Induction therapy

Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd), will will be administered.

DRUG

Fludarabine

Fludarabine will be administered as intravenous infusion.

Trial Locations (6)

28041

RECRUITING

Hosp. Univ. 12 de Octubre, Madrid

31008

RECRUITING

Clinica Univ. de Navarra, Pamplona

37007

RECRUITING

Hosp Clinico Univ de Salamanca, Salamanca

39008

RECRUITING

Hosp. Univ. Marques de Valdecilla, Santander

41013

RECRUITING

Hosp. Virgen Del Rocio, Seville

08036

RECRUITING

Hosp. Clinic de Barcelona, Barcelona

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY